Patent ID: 7858389
Filing Date: 2010-12-28
Classification: G16B,Y10T

Abstract:
1. A method of determining whether a non-small cell lung cancer (NSCLC) patient is likely to benefit from treatment with a monoclonal antibody drug targeting the EGFR pathway, comprising the steps of: a) obtaining a mass spectrum from a blood-based sample from the NSCLC patient; b) performing one or more predefined pre-processing steps on the mass spectrum obtained in step a); c) obtaining integrated intensity values of selected features in said spectrum at one or more predefined m/z ranges after the pre-processing steps on the mass spectrum in step b) have been performed; and d) using the values obtained in step c) in a classification algorithm using a training set comprising class-labeled spectra produced from blood-based samples from other cancer patients to identify the NSCLC patient as being either likely or not likely to benefit from treatment with the said monoclonal antibody drug targeting the EGFR pathway; wherein the said monoclonal antibody drug targeting the EGFR pathway is selected from the group of drugs consisting of cetuximab or the equivalent and panitumumab or the equivalent.